Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones.

J Clin Invest. 1997 Jul 1;100(1):136-41. Unique Identifier : AIDSLINE MED/97347426
Schnyder B; Mauri-Hellweg D; Zanni M; Bettens F; Pichler WJ; Institute of Immunology and Allergology, Inselspital, CH-3010-Bern,; Switzerland.


Abstract: T cells can recognize small molecular compounds like drugs. It is thought that covalent binding to MHC bound peptides is required for such a hapten stimulation. Sulfamethoxazole, like most drugs, is not chemically reactive per se, but is thought to gain the ability to covalently bind to proteins after intracellular drug metabolism. The purpose of this study was to investigate how sulfamethoxazole is presented in an immunogenic form to sulfamethoxazole-specific T cell clones. The stimulation of four CD4(+) and two CD8(+) sulfamethoxazole-specific T cell clones by different antigen-presenting cells (APC) was measured both by proliferation and cytolytic assays. The MHC restriction was evaluated, first, by inhibition using anti-class I and anti-class II mAb, and second, by the degree of sulfamethoxazole-induced stimulation by partially matched APC. Fixation of APC was performed with glutaraldehyde 0.05%. The clones were specific for sulfamethoxazole without cross-reaction to other sulfonamides. The continuous presence of sulfamethoxazole was required during the assay period since pulsing of the APC was not sufficient to induce proliferation or cytotoxicity. Stimulation of clones required the addition of MHC compatible APC. The APC could be fixed without impairing their ability to present sulfamethoxazole. Sulfamethoxazole can be presented in an unstable, but MHC-restricted fashion, which is independent of processing. These features are best explained by a direct, noncovalent binding of sulfamethoxazole to the MHC-peptide complex.
Keywords: *Antigen-Presenting Cells/IMMUNOLOGY *CD4-Positive T-Lymphocytes/IMMUNOLOGY *CD8-Positive T-Lymphocytes/IMMUNOLOGY *Drug Hypersensitivity/IMMUNOLOGY *Major Histocompatibility Complex *Receptors, Antigen, T-Cell, alpha-beta/IMMUNOLOGY *Sulfamethoxazole/IMMUNOLOGYKWDantigen-presentingcells/immunologyKWDcd4-positivet-lymphocytes/immunologyKWDcd8-positivet-lymphocytes/immunologyKWDdrughypersensitivity/immunologyKWDmajorhistocompatibilitycomplexKWDreceptors,antigen,t-cell,alpha-beta/immunologyKWDsulfamethoxazole/immunology
971030
M97A1132

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .